for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

STAAR Surgical Company

STAA.OQ

Latest Trade

37.32USD

Change

0.27(+0.73%)

Volume

76,844

Today's Range

37.15

 - 

37.78

52 Week Range

21.74

 - 

41.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
37.05
Open
37.18
Volume
76,844
3M AVG Volume
7.60
Today's High
37.78
Today's Low
37.15
52 Week High
41.26
52 Week Low
21.74
Shares Out (MIL)
44.61
Market Cap (MIL)
1,664.82
Forward P/E
203.57
Dividend (Yield %)
--

Next Event

Q4 2019 STAAR Surgical Co Earnings Release

Latest Developments

More

Staar Surgical Reports Q3 Earnings Per Share Of $0.05

STAAR Surgical Announces FDA IDE Clinical Study Approval

STAAR Surgical Co Sees 2019 Revenue Growth 20%

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About STAAR Surgical Company

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It manufactures lenses used in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. As of December 29, 2017, the Company sold its products in over 75 countries, with distribution in the United States, Canada, Japan and Spain.

Industry

Medical Equipment & Supplies

Contact Info

1911 Walker Ave

+1.626.3037902

http://www.staar.com

Executive Leadership

Louis E. Silverman

Independent Chairman of the Board

Caren L. Mason

President, Chief Executive Officer, Director

Deborah J. Andrews

Chief Financial Officer

Hans-Martin Blickensdoerfer

Senior Vice President - Commercial Operations, Direct Markets Europe and China

James E. Francese

Senior Vice President - Commercial Operations, North American and APAC

Key Stats

1.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.300

2017

-0.050

2018

0.110

2019(E)

0.182
Price To Earnings (TTM)
199.49
Price To Sales (TTM)
11.68
Price To Book (MRQ)
11.15
Price To Cash Flow (TTM)
135.46
Total Debt To Equity (MRQ)
2.39
LT Debt To Equity (MRQ)
0.32
Return on Investment (TTM)
5.88
Return on Equity (TTM)
4.93

Latest News

Latest News

BRIEF-STAAR Surgical Reports Q1 EPS Of $0.01

* STAAR SURGICAL REPORTS FIRST QUARTER 2018 RESULTS; REVENUE INCREASES 33 PERCENT ON ACCELERATING EVO VISIAN ™ ICL MOMENTUM

BRIEF-Staar Surgical Q4 Sales $24.9 Million

* STAAR SURGICAL REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-STAAR Surgical Sees ‍Double Digit Revenue Growth In FY 2018 Over 2017

* STAAR SURGICAL SEES DOUBLE DIGIT REVENUE GROWTH IN FULL YEAR 2018 OVER 2017 AND ICL UNIT GROWTH RANGE 15% TO 20% FOR 2018 Source text (http://bit.ly/2AFxyde) Further company coverage:

BRIEF-Staar Surgical reports Q3 earnings per share $0.03

* Q3 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S

BRIEF-Staar surgical appoints Scott Barnes, M.D. as chief medical officer

* Staar surgical appoints Scott Barnes, M.D. as chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Staar Surgical names Deborah Andrews as CFO

* Deborah Andrews, interim CFO, has agreed to resume her role as Chief Financial Officer for company Source text for Eikon: Further company coverage:

BRIEF-STAAR Surgical, Seoul/Busan BalGeunSeSang eye clinic announce strategic cooperation agreement

* STAAR Surgical and Seoul/Busan Balgeunsesang eye clinic announce strategic cooperation agreement

BRIEF-Staar Surgical Q2 loss per share $0.02

* Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Staar Surgical files for potential mixed shelf offering

* Staar Surgical Co files for potential mixed shelf offering of up to $200 million - SEC filing

BRIEF-STAAR Surgical announces CE Mark approval for the EVO+ visian ICL with aspheric (EDOF) optic

* STAAR Surgical announces CE Mark approval for the EVO+ Visian ICL with aspheric (EDOF) optic

BRIEF-Staar Surgical reports Q1 sales $20.4 million

* Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S

BRIEF-Staar Surgical names Deborah Andrews interim CFO

* Steve Brown has resigned his position as chief financial officer effective April 28, 2017 Source text for Eikon: Further company coverage:

BRIEF-Stephen Brown notifies intention to resign as chief financial officer of STAAR Surgical

* Stephen Brown notified co of his intention to resign as vice president and chief financial officer

BRIEF-Staar Surgical Q4 adjusted earnings per share $0.02

* Staar Surgical Co - on-going FDA remediation effort finished quarter on-track and on-budget

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up